EMA publishes additional reports on decision-making for orphan medicines, an initiative that addresses requests from stakeholders. The new reports summarise the reasoning of the Agency’s Committee for Orphan Medicinal Products (COMP) on whether or not a medicine designated as an orphan medicine during its development still fulfils the designation criteria at the time of its authorisation.

Read more: https://lnkd.in/ekcu8uq